ALSO NOTED: Acorda gains $10M in funds; Supreme Court debates patent law; and much more...

> Acorda Therapeutics has amended its deal with Paul Capital Healthcare to gain up to $10 million in additional funds. Release

> Pain Therapeutics says its painkiller PTI-202 successfully completed a Phase I trial. Release

> The U.S. Supreme Court debated a critical test of U.S. patent law in a case that has broad implications for the biotech industry. Report

> While citing progress in containing bird flu in Asia, the UN's bird flu chief says it will need another $1.3 billion to fight the spread of H5N1 in Africa and other countries. Report

> Novartis is mulling over the sale of the baby food company Gerber. It's already in talks to sell a medical nutrition subsidiary to Nestle. Report (WSJ sub. req.)

> Auxilium Pharmaceuticals has amended its manufacturing agreement with UK-based Cobra Biologics. Under the amended agreement, Cobra will complete only one BLA batch of the active ingredient for AA4500, its injectable enzyme. Release

> Arena Pharmaceuticals plans to sell eight million shares in a public offering. Report

> Zila says it has completed its transition to a cancer detection company. Release

And Finally… Confronted by the embarrassing scandal surrounding the fraudulent Korean stem cell study in 2004, Science magazine has devised new methods to scrutinize research findings. Article

Suggested Articles

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.

Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.

The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.